Your browser is no longer supported. Please, upgrade your browser.
CRVS [NASD]
Corvus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.21 Insider Own12.76% Shs Outstand29.66M Perf Week3.19%
Market Cap111.45M Forward P/E- EPS next Y-1.16 Insider Trans124.25% Shs Float23.45M Perf Month-1.02%
Income-6.00M PEG- EPS next Q-0.33 Inst Own47.70% Short Float5.71% Perf Quarter-28.68%
Sales- P/S- EPS this Y87.20% Inst Trans7.53% Short Ratio1.34 Perf Half Y-30.88%
Book/sh2.43 P/B1.20 EPS next Y17.50% ROA-63.60% Target Price- Perf Year-13.13%
Cash/sh1.16 P/C2.52 EPS next 5Y- ROE-78.80% 52W Range2.51 - 6.88 Perf YTD-18.26%
Dividend- P/FCF- EPS past 5Y33.30% ROI- 52W High-57.70% Beta1.65
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low15.94% ATR0.16
Employees42 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)50.79 Volatility7.03% 5.92%
OptionableYes Debt/Eq0.00 EPS Q/Q345.40% Profit Margin- Rel Volume0.13 Prev Close2.94
ShortableYes LT Debt/Eq0.00 EarningsApr 29 AMC Payout- Avg Volume1.00M Price2.91
Recom2.30 SMA204.08% SMA50-2.80% SMA200-22.19% Volume133,674 Change-1.02%
Feb-10-21Downgrade Mizuho Buy → Neutral $7 → $4
Sep-12-19Initiated Mizuho Buy
May-29-19Initiated ROTH Capital Buy $6
Aug-24-17Upgrade Credit Suisse Underperform → Neutral
May-01-17Downgrade Credit Suisse Neutral → Underperform
Apr-18-16Initiated Guggenheim Buy
Apr-18-16Initiated Credit Suisse Outperform
May-05-21 09:00AM  
Apr-29-21 04:05PM  
Apr-20-21 02:51AM  
Mar-25-21 08:30AM  
Mar-05-21 08:30AM  
Feb-18-21 11:38PM  
Feb-17-21 04:10PM  
Feb-12-21 09:00AM  
Feb-11-21 04:01PM  
Feb-04-21 09:57AM  
07:30AM  
Jan-30-21 02:53AM  
Dec-07-20 03:28PM  
Dec-06-20 10:00AM  
Nov-30-20 08:00AM  
Nov-11-20 04:05PM  
Nov-09-20 08:05AM  
Nov-02-20 08:00AM  
Nov-01-20 09:08AM  
Oct-29-20 04:00PM  
08:30AM  
Oct-07-20 10:39AM  
Oct-05-20 09:57AM  
09:48AM  
08:05AM  
07:24AM  
07:22AM  
Sep-17-20 03:01AM  
Sep-11-20 08:30AM  
Sep-10-20 08:30AM  
Sep-08-20 06:02PM  
Aug-04-20 04:05PM  
Aug-03-20 11:33AM  
Jul-30-20 04:02PM  
Jul-23-20 08:30AM  
Jul-20-20 03:30PM  
Jul-09-20 08:43AM  
Jul-08-20 10:22AM  
09:58AM  
Jul-07-20 09:53AM  
09:32AM  
08:51AM  
07:00AM  
Jul-03-20 06:12PM  
Jun-24-20 08:40AM  
May-29-20 08:00AM  
May-27-20 08:00AM  
May-20-20 12:00PM  
May-13-20 05:23PM  
May-04-20 07:26AM  
Apr-30-20 04:05PM  
Apr-22-20 08:30AM  
Mar-10-20 05:14PM  
Mar-05-20 04:05PM  
Feb-28-20 04:01PM  
Feb-19-20 04:05PM  
Feb-13-20 08:00AM  
Feb-01-20 02:00PM  
Dec-20-19 10:56AM  
Dec-17-19 06:28AM  
Dec-07-19 09:00AM  
Nov-08-19 07:00AM  
Nov-07-19 08:30AM  
Nov-05-19 08:30AM  
Nov-04-19 08:30AM  
Nov-02-19 01:01AM  
Oct-29-19 04:05PM  
Oct-18-19 11:01AM  
Oct-17-19 08:30AM  
Oct-03-19 08:30AM  
Sep-03-19 01:28PM  
Aug-10-19 11:17AM  
Aug-07-19 04:05PM  
Aug-01-19 04:05PM  
Jul-24-19 04:15PM  
Jul-03-19 11:14AM  
Jun-02-19 10:45AM  
May-28-19 08:30AM  
May-25-19 01:28PM  
May-16-19 08:30AM  
May-09-19 05:05PM  
04:02PM  
May-01-19 04:10PM  
Apr-26-19 03:07PM  
Mar-07-19 04:10PM  
Mar-05-19 04:15PM  
Feb-06-19 08:30AM  
Jan-30-19 08:30AM  
Jan-28-19 04:05PM  
Jan-22-19 12:05PM  
Jan-10-19 08:30AM  
Jan-08-19 08:30AM  
Dec-28-18 08:52AM  
Nov-23-18 09:03AM  
Nov-13-18 07:30AM  
Nov-12-18 08:30AM  
Nov-10-18 05:00PM  
Nov-05-18 06:31PM  
Nov-02-18 05:12AM  
Nov-01-18 04:10PM  
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLER RICHARD A MDPresident and CEOMay 04Buy2.8035,71499,99935,714May 05 05:01 PM
MILLER RICHARD A MDPresident and CEOFeb 17Buy3.50100,000350,0001,278,515Feb 17 04:44 PM
ORBIMED ADVISORS LLCDirectorFeb 17Buy3.501,285,7144,499,9998,053,298Feb 19 04:52 PM
Thompson Peter A.DirectorFeb 17Buy3.501,285,7144,499,9998,053,298Feb 19 04:47 PM
Novo Holdings A/S10% OwnerJul 08Sale5.37741,4403,985,1661,389,498Jul 09 04:35 PM
Novo Holdings A/S10% OwnerJul 07Sale5.25796,6224,183,3812,130,938Jul 09 04:35 PM